AbbVie Inc. (FRA:4AB)
Germany · Delayed Price · Currency is EUR | Market Cap | 331.75B +12.7% |
| Revenue (ttm) | 50.83B +7.4% |
| Net Income | 2.00B -53.4% |
| EPS | 1.13 -54.0% |
| Shares Out | n/a |
| PE Ratio | 165.78 |
| Forward PE | 16.97 |
| Dividend | 5.75 (3.13%) |
| Ex-Dividend Date | Jan 16, 2026 |
| Volume | n/a |
| Average Volume | 144 |
| Open | 183.60 |
| Previous Close | 184.20 |
| Day's Range | 183.60 - 183.60 |
| 52-Week Range | 147.00 - 209.50 |
| Beta | n/a |
| RSI | 42.53 |
| Earnings Date | Feb 4, 2026 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial numbers in USD Financial StatementsNews
Better Long-Term Buy: This Emerging Player or the Industry Leader?
AbbVie is a well-established drugmaker with fast-growing immunology products and a solid dividend program. Abivax could challenge pharmaceutical giants like AbbVie in a niche of the immunology market.
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability...
10 Highest Rated Dividend Kings For Generations Of Income
My top 10 Dividend Kings list prioritizes reliability, dividend safety, and attractive valuation for long-term, generational income. Selection criteria include payout ratios under 70%, strong dividend...
AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships
~3 out of 4 respondents said migraine attacks have stood in the way of romantic relationships, according to new Harris Poll survey Wife, mother, country music star, and entrepreneur Jessie James Decke...
Why AbbVie Stock Trounced the Market in 2025
The pharmaceutical sector mainstay has built an impressive and resilient portfolio. Fears of serious declines in the fundamentals following the loss of patent exclusivity for Humira were overblown.
AbbVie, SLB, Amphenol, And More On CNBC's 'Final Trades'
On CNBC's “ Halftime Report Final Trades ,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he likes AbbVie Inc. (NYSE: ABBV) and recommended staying long on the s...
Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine
- N ine e-posters presenting comprehensive Allergan Aesthetics portfolio data spanning first-in-class botulinum neurotoxin serotype E (TrenibotulinumtoxinE, "TrenibotE"), onabotulinumtoxinA, hyaluron...
US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major pharmaceutical companies including Eli Lilly , Pfizer and AbbVie for the third cycle of the M...
Final Trades: AbbVie, SLB, Amphenol and the IYH
The Investment Committee give you their top stocks to watch for the second half.
Citigroup Adjusts Price Target for AbbVie (ABBV) to $230, Maintaining Neutral Rating | ABBV ...
Citigroup Adjusts Price Target for AbbVie (ABBV) to $230, Maintaining Neutral Rating | ABBV Stock News
Hobart Private Capital, LLC Buys 487 Shares of AbbVie Inc (ABBV)
Hobart Private Capital, LLC Buys 487 Shares of AbbVie Inc (ABBV)
The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator
CHICAGO--(BUSINESS WIRE)--The AbbVie Foundation, a 501(c)(3) nonprofit working to drive transformative change and advance health equity in communities worldwide, in partnership with MATTER, the premie...
Next Level Wealth Planning, LLC Buys 4,651 Shares of AbbVie Inc (ABBV)
Next Level Wealth Planning, LLC Buys 4,651 Shares of AbbVie Inc (ABBV)
INVESTED ADVISORS Buys 244 Shares of AbbVie Inc (ABBV)
INVESTED ADVISORS Buys 244 Shares of AbbVie Inc (ABBV)
MOKAN Wealth Management Inc. Buys 2,134 Shares of AbbVie Inc (ABBV)
MOKAN Wealth Management Inc. Buys 2,134 Shares of AbbVie Inc (ABBV)
Spectrum Asset Management, Inc. (NB/CA) Sells 2,472 Shares of AbbVie Inc (ABBV)
Spectrum Asset Management, Inc. (NB/CA) Sells 2,472 Shares of AbbVie Inc (ABBV)
BCS Wealth Management Buys 3,040 Shares of AbbVie Inc (ABBV)
BCS Wealth Management Buys 3,040 Shares of AbbVie Inc (ABBV)
The Best Dividend Stocks to Buy and Hold Forever
AbbVie is a Dividend King with a juicy yield. Coca-Cola has increased its dividend for 63 consecutive years and will likely soon extend that streak.
Best Dividend Kings: January 2026
Dividend Kings underperformed SPY in 2025, averaging 4.91% total return versus SPY's 17.72%, though 14 Kings outperformed the index. 2026 began strongly for Dividend Kings, up 4.66% through January 23...
Voya Global Income & Growth Fund Buys 4,085 Shares of AbbVie Inc (ABBV)
Voya Global Income & Growth Fund Buys 4,085 Shares of AbbVie Inc (ABBV)
Patent rejected for MNC’s cancer drug, generics to follow
The Indian Patent Office has rejected AbbVie's patent application for its cancer drug Venetoclax, citing a lack of inventive step and no enhancement in therapeutic efficacy. This decision, if upheld, ...
Noteworthy ETF Outflows: IWB, JNJ, MA, ABBV
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an appro...
2 High-Yielding Dividend Stocks That Retirees Can Rely on for Recurring Income
AbbVie and Coca-Cola are blue-chip stocks that have excellent financials. These two stocks proved resilient in 2022, rising in value while the markets crashed.
HAGER INVESTMENT MANAGEMENT SERVICES, LLC Sells 268 Shares of AbbVie Inc (ABBV)
HAGER INVESTMENT MANAGEMENT SERVICES, LLC Sells 268 Shares of AbbVie Inc (ABBV)